WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma
Alexander Rialdi, Mary E. Duffy, Alex P. Scopton, Frank Fonseca, Julia N. Zhao, Megan Schwarz, Pedro Molina-Sánchez, Slim Mzoughi, Elisa Arceci, Jordi Abril‐Fornaguera, Austin Meadows, Marina Ruiz de Galarreta, Denis Torre, Kyna Reyes, Yan Ting Lim, Felix Rosemann, Z.M. Khan, Kevin Mohammed, Xuedi Wang, Xufen Yu, Manikandan Lakshmanan, Ravisankar Rajarethinam, Soo‐Yong Tan, Jian Jin, Augusto Villanueva, Eleftherios Michailidis, Ype P. de Jong, Charles M. Rice, Ivan Marazzi, Dan Hasson, Josep M. Llovet, Radoslaw M. Sobota, Amaia Lujambio, Ernesto Guccione, Arvin C. Dar
Topics & Concepts
Wnt signaling pathwayKinaseHepatocellular carcinomaMAPK/ERK pathwayCancer researchMutantCateninProtein kinase AEZH2p38 mitogen-activated protein kinasesBiologySignal transductionCell biologyEpigeneticsBiochemistryGeneCancer Mechanisms and Therapy14-3-3 protein interactionsPI3K/AKT/mTOR signaling in cancer